AIP-204

AIP-204 is a therapeutic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP Medical) for the treatment of lung cancer. Currently in the preclinical stage of development, AIP-204 is designed to selectively target lung cancer cells and deliver localized ionizing radiation to induce tumor cell death while minimizing exposure to healthy surrounding tissues. As part of AIP Medical's oncology pipeline, this agent represents a targeted approach to lung cancer therapy. Specific details regarding its molecular target, radioisotope, and chemical structure have not been publicly disclosed by the developer.